Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer

doi:10.3748/wjg.v20.i29.9732

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 29

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7513)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

478

WORD

227

HTML

3811

Tables (1-1)

192

Sum=4708

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

693

Download

604

Sum=1297

Publishing Process of This Article

Item

Count

Browse

861

Download

647

Sum=1508

Aug 7, 2014 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Aug 7, 2014; 20(29): 9732-9743
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9732

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer

Alfonso De Stefano, Chiara Carlomagno

Alfonso De Stefano, Chiara Carlomagno, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy

Author contributions: Both authors contributed to this paper equally.

Correspondence to: Alfonso De Stefano, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. alfonso.destefano@unina.it

Telephone: +39-817-463660 Fax: +39-812-203147

Received: October 27, 2013
Revised: February 13, 2014
Accepted: March 12, 2014
Published online: August 7, 2014

Abstract

Systematic analysis of the epidermal growth factor receptor (EGFR) pathway revealed that biomarkers could be used to predict the response to and outcome of anti-EGFR therapies in patients affected by metastatic colorectal cancer. We have conducted a review on the most recent findings and advances on this topic. To this aim, we searched the PubMed database for articles devoted to predictive and prognostic biomarkers for patients administered cetuximab- and panitumumab-based therapies. Here we review the state of the art and the controversies about the molecular factors known to be predictors of the efficacy of anti-EGFR therapy, namely, KRAS, BRAF, NRAS, PI3KCA and PTEN, and we discuss their prognostic value in colorectal cancer patients.

Keywords: KRAS, Anti-epidermal growth factor receptor, Metastatic colorectal cancer, Biomarkers

Core tip: This is a review underlining the importance of biomarkers in the treatment of metastatic colorectal cancer. All most recent findings are described to offer a contribution to define a correct approach to anti-epidermal growth factor receptor based treatment.